BioSpace News Archive

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema.

Shoulder Innovations Inc, a leading innovator in the development of shoulder replacement systems, announced that they have received FDA clearance for their InSet™ Reverse Shoulder Arthroplasty System.

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.

Genevant Sciences announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m. ET.

Halberd Corp. announced filing a U. S. joint provisional patent application, “Treating Alzheimer’s Disease Utilizing Extracorporeal Radio Frequency.” The innovation is a result of Halberd’s Sponsored Research conducted at Arizona State University and Youngstown State University.

Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Brazil’s National Health Surveillance Agency (ANVISA) has approved Dojolvi® (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Legend Biotech Corporation today reported its 2021 second quarter unaudited financial results.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately.